Search

everythinglearnresearchcommunity

for

Search:↓

Platelet-rich plasma can increase hair density and may help treat some skin conditions, but it's costly, not FDA-approved, and needs more research.

Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.

Lavender is widely used for its calming effects and in beauty products, but its medical effectiveness is not fully proven and not FDA-approved.

Exosomes, tiny cell-released particles, may help hair growth, but their exact role is unclear, they're not FDA-approved, and their unregulated use can cause side effects.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Finasteride and minoxidil are approved treatments for hair loss, and hair transplants can be effective but require careful patient selection.

The committee decided not to approve the drug due to low effectiveness and high risks.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Children with alopecia areata need supportive care and off-label treatments due to a lack of approved options.

New treatments for child hair loss due to immune issues are effective but not yet officially approved.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Female pattern hair loss is common and should be treated early to prevent worsening, with Minoxidil being the main approved treatment.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Lasers and light treatments are now the most common ways to remove hair.

Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.

Certain compounds can boost hair and nail growth.

Aminoacridine and Minoxidil together show promise for better hair and nail growth.

Deoxycholic acid is effective for reducing chin fat but can cause side effects and serious complications, so careful patient evaluation is needed.

Old psychiatric drugs are increasingly being used for new purposes, and technologies like SmartCube® help create new drugs.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

The document concludes that current hair loss treatments have limitations and suggests researching new treatments targeting different factors of hair loss.

Provenge extends prostate cancer survival by about 4 months.

Baricitinib effectively regrows hair in severe alopecia areata cases.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Isotretinoin shows promise as a treatment for Chagas disease by effectively inhibiting key transporters in the parasite.